First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
13 Julio 2023 - 6:15AM
Business Wire
Leading healthcare intelligence organisation
most awarded CRO in 2023 CRO Leadership Awards
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence
and clinical research organisation, has received positive
recognition from leading business and industry organisations as a
leading CRO of choice and a top-rated employer in the first half of
2023.
For its excellent performance in clinical research, ICON was
named a recipient of the 2023 CRO Leadership Awards in the
following categories: Capabilities, Compatibility, Expertise,
Quality and Reliability. Each category has a rating for Big Pharma,
Small Pharma and Overall, with ICON rating in 14 out of 15 possible
ratings. These awards are the result of an annual CRO Quality
benchmarking research conducted by ISR Reports via an online
survey. 46 service providers were evaluated. This year, ICON was
the most awarded CRO across over 20 performance metrics, including
being rated ‘Top Performer’ for ‘Operational excellence’,
‘Therapeutic expertise’ and ‘Meeting project timelines’. ICON was
also rated as ‘Exceeding customer expectations’ for ‘Data quality’
and ‘Technology for access to data’. This is the sixth consecutive
year ICON has been awarded.
ICON was also included in Forbes’ list of America’s Best Large
Employers 2023, the fourth time the company has been featured on
the list. The list is compiled by Forbes in partnership with
Statista and is based on a survey of approximately 45,000 workers
at American companies and institutions with 5,000 or more
employees. For its efforts in promoting diversity and inclusion,
ICON has also been included in the Financial Times European Leader
in Diversity 2023 Award List, where it was ranked 80 out of 850
companies.
ICON was the recipient of the 2023 Global Impact Award from the
American Chamber of Commerce Ireland as part of its US-Ireland
Awards series. The Global Impact Award recognises a team or
organisation that has had a significant positive, international
impact on markets or society in areas including but not limited to
research, development and innovation, talent development or
digitisation/artificial intelligence. ICON was recognised for its
role in the search for vaccines and treatments for COVID-19,
specifically its partnership on Pfizer and BioNTech's
investigational COVID-19 vaccine programme.
Steve Cutler, CEO, ICON commented: “Driving positive outcomes
and value for our customers and the patients we serve is hugely
important to us. These awards recognise the quality of our services
and the commitment of our people right across the ICON
business.”
Further recognition was given to ICON’s Creative and Digital
Services and its Insights, Evidence and Value team. They were
presented with a silver award by healthcare marketing industry
publication, PM360, for a Creole-language breast cancer screening
campaign called ‘“What’s Your Reason”, run in partnership with
Genentech. The campaign aimed to encourage conversations about
breast cancer screenings within the Black Haitian-American
population in the United States. The approach used data and
messaging that was translated into Creole, along with a logo that
was adapted to visually represent the core audience.
Both the teams were also awarded a gold award at the 2023 Viddy
Awards, in the branded content category for the “EUTHYROX®
Promotional Video”. The Creative and Digital Services team, along
with the PubsHub team, separately won gold in the marketing
category for the “Journals and Congresses PubsHub Software
Solutions Promotional Video”.
Additionally, the Digital Operations Team at ICON was named ‘IT
Professional Team of the Year’ at the Tech Excellence 2023 Awards
in Ireland.
A full list of ICON’s industry awards can be viewed at
https://www.iconplc.com/news-events/awards/.
Ends
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical
research organisation. From molecule to medicine, we advance
clinical research providing outsourced services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. We develop new innovations, drive emerging therapies
forward and improve patient lives. With headquarters in Dublin,
Ireland, ICON employed approximately 41,150 employees in 109
locations in 53 countries as at March 31, 2023. For further
information about ICON, visit: www.iconplc.com.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230713464155/en/
Media contacts: Claire Quinn (GMT time zone) Corporate
Communications, ICON plc claire.quinn@iconplc.com +353 87
4066091
Weber Shandwick (PR adviser) Lisa Henry (GMT time zone) +447785
458203 lhenry@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
ICON (NASDAQ:ICLR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024